VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Vergote, I. B., Fidalgo, A. P., Hamilton, E., Valabrega, G., Van Gorp, T., Sehouli, J., … Makker, V. (2022). VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Annals of Oncology, 33(4), 448–450. https://doi.org/10.1016/j.annonc.2022.02.223